Historic Liabilities and Shareholders Equity for Nuvation Bio (NUVB) over the last 4 years, with Jun 2025 value amounting to $647.2 million.
- Nuvation Bio's Liabilities and Shareholders Equity rose 8.81% to $647.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.7 billion, marking a year-over-year decrease of 6.93%. This contributed to the annual value of $540.6 million for FY2024, which is 13.01% down from last year.
- Latest data reveals that Nuvation Bio reported Liabilities and Shareholders Equity of $647.2 million as of Q2 2025, which was up 31.42% from $492.5 million recorded in Q1 2025.
- Nuvation Bio's 5-year Liabilities and Shareholders Equity high stood at $832.1 million for Q1 2021, and its period low was $492.5 million during Q1 2025.
- Over the past 3 years, Nuvation Bio's median Liabilities and Shareholders Equity value was $622.0 million (recorded in 2023), while the average stood at $606.1 million.
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 475,757.17% in 2021, then dropped by 19.68% in 2025.
- Over the past 5 years, Nuvation Bio's Liabilities and Shareholders Equity (Quarterly) stood at $797.8 million in 2021, then fell by 13.95% to $686.5 million in 2022, then decreased by 8.10% to $630.9 million in 2023, then fell by 9.40% to $571.6 million in 2024, then grew by 8.81% to $647.2 million in 2025.
- Its Liabilities and Shareholders Equity was $647.2 million in Q2 2025, compared to $492.5 million in Q1 2025 and $571.6 million in Q3 2024.
